Search
for
Sort by
Research 151–180 of 331
- Adverse Dermatologic Effects of Cardiovascular Drug Therapy: Part III
- A Case of Rhupus with Rowell Syndrome
- A Case of Rhupus with Rowell Syndrome
- Pneumonitis Caused by Metronidazole
- DP15 Syphilis: the chameleon disease. A case series of unexpected mimicry
- Dizziness and rash in an HIV positive man
- A study of COVID‐19 vaccine (Covishield) induced dermatological adverse effects from India
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
- New onset of alopecia areata in a patient with SARS‐CoV‐2 infection: Possible pathogenetic correlations?
- Early Diffuse Alopecia in a Neonate with Congenital Syphilis
- Dermoscopy in General Dermatology: A Practical Overview
- Fatal Toxic Epidermal Necrolysis Associated With Cetuximab in a Patient With Colon Cancer
- Fatal Toxic Epidermal Necrolysis Associated with Minoxidil
- Heterogeneous red–white discoloration of the nail bed and distal onycholysis in a patient with COVID‐19
- Hair Loss Induced by Lopinavir-Ritonavir
- Cutaneous Mastocytosis Associated With Congenital Alopecia
- Dermatologic Adverse Events from Cancer Treatments
- Diffuse Hair Loss in Secondary Syphilis in HIV Positive Man: Case Report
- Malarone® induced pancreatitis and alopecia in a dog: a case report
- Immune response involving the bulge region in addition to telogen conversion contributes to hair loss in a case of atypical drug-induced hypersensitivity syndrome
- After Math of COVID Through Eyes of Tricoscopy
- British Society for Dermatopathology: Summaries of Papers
- Severe and Fatal Phenobarbitone Eruptions
- Omeprazole-induced hypertrichosis in two children
- The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults
- Recognition and management of <i>Staphylococcus aureus</i> toxin‐mediated disease
- Cutaneous manifestations of systemic lupus erythematosus
- Cutaneous reactions to recombinant cytokine therapy
- Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors
- THE DISEASE SPECTRUM, EPIDEMIOLOGY, AND ETIOLOGY OF TOXIC-SHOCK SYNDROME